AI can predict premature death among people with inflammatory bowel disease: study
TORONTO — A new study suggests AI can predict premature death among people who have inflammatory bowel disease, also known as Crohn's and colitis.
Researchers used machine learning to analyze data from more than 9,000 people in Ontario who had IBD and died between 2010 and 2020.
The study, published today in the Canadian Medical Association Journal, found half of those deaths were before age 75, which is considered a premature death.
People were most likely to have died prematurely if they had been diagnosed with certain other chronic conditions — including arthritis, high blood pressure, kidney failure, cancer and mental health issues — before age 61.
Senior author Dr. Eric Benchimol, a pediatric gastroenterologist, says people don't usually die of inflammatory bowel disease itself.
He says the research findings show the need to watch for other chronic conditions in people with IBD and treat those as early as possible.
"I think what's important here is that we need to be aware that it can't be a gastroenterologist working in isolation anymore," said Benchimol, who practices at Sick Kids Hospital and is also a senior scientist at the Institute for Clinical Evaluative Sciences (ICES), which provided the patient data for the study.
"We really need to be aware of all of these other things that are happening to the people with IBD, and try to get them a system of co-ordinated care."
Crohn's and colitis inflame the lining of the gastrointestinal tract and interfere with the body's ability to digest food and absorb nutrients, according to Crohn's and Colitis Canada. Instead of normal bowel movements, patients suffer from "feelings of urgency, diarrhea, and bloody stool."
It's believed to be caused by a combination of genetics and environmental factors that affect the gut microbiome, Benchimol said, noting that smoking and early use of antibiotics are two factors thought to be associated with the disease.
IBD is quite common in Canada and the rate of cases is growing, he said. By 2035, more than one in 100 people in the country are expected to have the disease.
Benchimol said the specific chronic diseases identified alongside IBD in the study "unfortunately weren't that much of a surprise."
"I specialize in children with IBD, and we see some of these diseases all the time. Like we see arthritis. We see mood and anxiety disorders in kids with IBD. And teens with IBD are much more likely to have anxiety and depression than their peers," he said.
What's surprising — and worrisome — is the association of those conditions with early death, he said, noting more research is needed to determine how or why those deaths happen.
In addition to AI, the researchers used traditional statistical models to determine the factors linked to premature death among people with IBD and the results were consistent, boosting confidence in the accuracy of machine learning, Benchimol said.
Machine learning can process much more data and find relationships between different factors better than humans can, he said, noting that future studies using AI will track people who are living with IBD and include additional clinical variables such as how bad their inflammation is and what medications they are taking.
Benchimol hopes AI will be a way to figure out not only how to prevent premature death among people who have the disease, but ultimately how to prevent it altogether.
"We're going to end up using machine learning to try to understand what environmental risk factors might predispose people to getting IBD in the first place in a way that maybe we can't think of with our own brains," he said.
This report by The Canadian Press was first published March 24, 2025.
Canadian Press health coverage receives support through a partnership with the Canadian Medical Association. CP is solely responsible for this content.
Nicole Ireland, The Canadian Press
Hashtags

Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
2 days ago
- Yahoo
If You Have Ulcerative Colitis, You May Want to Watch Out for This Type of Fiber
You've probably heard the adage, 'An apple a day keeps the doctor away.' But the opposite can actually be true if you have ulcerative colitis (UC), an inflammatory bowel disease (IBD) that causes symptoms like bloating, cramping, and diarrhea. That's because apples, as well as other foods like nuts and whole grains, are rich in a nutrient called insoluble fiber that may trigger symptoms or exacerbate them during flare-ups. Here's what everyone with UC should know about this type of fiber, including when to avoid it and how to get enough of the nutrient. While soluble fiber dissolves in water and forms a gel-like substance to bulk up stools and promote digestion, insoluble fiber is generally coarse and remains intact as it goes through the body, making it more challenging to digest, Ritu Nahar, MD, a gastroenterologist with Allied Digestive Health in New Jersey, tells SELF. 'With UC, the colon's lining is inflamed and ulcerated, which makes it more sensitive to rough, bulky fibers,' she explains. 'The irritation it causes can be really uncomfortable,' adds Danielle Barsky, MS, RD, a registered dietitian at Los Angeles' Cedars-Sinai Medical Center who specializes in treating people with IBD. Insoluble fiber can also trigger symptoms and worsen flares, exacerbating symptoms like diarrhea, cramping, and the urge to go, she adds This question isn't exactly straightforward to answer because many foods contain both types of fiber, says Dr. Nahar. Take apples, for example. The flesh of the apple has soluble fiber, while the skin has insoluble fiber. With broccoli, the florets (a.k.a. the green 'tree top' part of the veggie) contain soluble fiber, while the stem has insoluble fiber. However, generally speaking, insoluble fiber is commonly found in whole grains, bran, legumes, nuts, seeds, produce skins, and tough vegetables and fruits. Common examples that should be avoided include: Vegetables like artichokes, asparagus, bok choy, Brussels sprouts, cabbage, celery, collard greens, corn, fennel, green onion, kale, kohlrabi, leeks, lettuce, mushrooms, okra, peas, peppers, radish, snap peas, snow peas, spinach, and Swiss chard. Fruits like blackberries, blueberries, cherries, coconut meat, cranberries, dragon fruit, figs, grapes, kiwifruit, olives, passion fruit, pineapple, pomegranate, raspberries, rhubarb, strawberries. Grains like amaranth, bran, buckwheat, bulgar, pumpernickel, rye, whole grains, whole spelt, whole wheat, steel cut oatmeal, brown and wild rice, buckwheat, and quinoa. Whole nuts and seeds, as well as chunky nut or seed butter spreads. Whole legumes, including beans, peas, lentils, edamame, and tempeh. Snacks like popcorn, corn chips, and corn nuts. You may have heard conflicting advice about consuming fiber during flare-ups, but it's essential for proper nourishment and maintaining a well-functioning digestive system. 'During a flare, patients often feel too nauseated or weak to eat, and high-fiber foods may seem unappetizing,' says Dr. Nahar. 'They may gravitate toward bland carbohydrates like white bread, crackers, or plain rice, which are easier to digest but lower in fiber.' If you can relate, definitely follow your gut, but try to prioritize good nutrition if you're able to tolerate it. Minimize foods rich in insoluble fiber, which can exacerbate your symptoms, but do your best to incorporate some sources of soluble fiber into your diet (like peeled apples, bananas, oats, and cooked carrots) that are more digestible, Barsky suggests. If you want to experiment with incorporating sources of insoluble fiber into your diet during or immediately following a flare when you're still more sensitive, Dr. Nahar suggests cooking or blending them. 'Cooking methods can make insoluble fiber more tolerable for those with UC. Steaming, roasting, and boiling help soften fiber, reducing its abrasive effect on the intestines,' she explains. Puréed pea soup, mashed sweet potatoes, and blended bean dips, such as hummus, can also be easier on the gut, as can jarred, canned, peeled, and steamed fruits and vegetables, she says. Getting enough fiber is essential when you're recovering from a flare-up. Research shows that soluble fiber, especially, can nourish the microbes that keep your intestines functioning normally. That's important during remission, as your body works to heal the lining of the gut and restore the right balance of bacteria, Dr. Nahar says. 'It also helps form softer, more cohesive stools and may reduce diarrhea and urgency during remission,' she adds. For individuals under 50 without UC, the general recommendation is to consume approximately 25 grams of fiber per day for women and 38 grams per day for men, with a balance of soluble and insoluble fiber. But this might be too much while recovering from a flare, notes Dr. Nahar, who suggests gradually reintroducing fiber as you can tolerate it. 'A rough target during remission [for both men and women] might be 15 to 25 grams per day, with a focus on well-tolerated foods,' says Dr. Nahar. Start with soluble fiber for about 50% of your intake, she advises. Testing your limits with insoluble fiber and UC is not a one-size-fits-all process. You may need to consult with a registered dietitian who specializes in IBD to personalize eating strategies to your specific diet and lifestyle, Barsky says. 'I always emphasize to patients that an individual's tolerance is variable,' adds Dr. Nahar. 'The goal is to balance fiber intake to support gut health without exacerbating inflammation.' Only you know what's best for your body. UC is an unpredictable condition that varies from person to person. You may not have much warning about when your next flare will be, but keeping your kitchen stocked with tolerable, soluble-fiber foods will help you be prepared and may give you peace of mind. Get more of SELF's great service journalism delivered right to your inbox. Related: Are There Certain Foods to Avoid With Ulcerative Colitis? 5 Women With Ulcerative Colitis Share What's Helped Them Stay Mentally Strong 3 Women on the Reality of Dating With Ulcerative Colitis Originally Appeared on Self
Yahoo
3 days ago
- Yahoo
I thought I was a healthy teen — I constantly dismissed a sign that turned out to be a chronic disease
Gracie Cappelle should have been looking forward to her freshman year at Texas State University. Instead, she got a crash course in ulcerative colitis (UC). 'I had never heard of ulcerative colitis,' Cappelle, 19, told The Post. 'It took me a really long time to even understand what was happening within my body.' Cappelle was diagnosed with the chronic disease in the summer of 2024. She spent her freshman year eliminating dairy and fatty foods from her diet — not easy as a college student — in the hopes of managing her symptoms since there's no cure for UC. About a million Americans are believed to have UC, the most common type of inflammatory bowel disease. Experts aren't exactly sure what causes the condition, but they think it's related to abnormal immune system reactions. Inflammation and ulcers develop in the lining of the colon and rectum, often causing stomach pain, bloody diarrhea and frequent bowel movements. Crohn's disease is similar but can affect any part of the GI tract. UC is most often diagnosed in people 15 to 30 years old. Adults between 50 and 70 are also at higher risk. Cappelle didn't immediately realize that something was amiss. She occasionally noticed blood in her stool but figured it was no big deal. 'It wasn't bad at first,' Cappelle recalled. 'I looked it up a couple of times, and the only two things that would come up were internal hemorrhoids or colon cancer. And I was like, 'OK, well, I don't have colon cancer, so it's probably just internal hemorrhoids.' So I wasn't worried about it.' The bleeding eventually intensified to the point where it was happening every day — and she found herself rushing to the bathroom more often. A colonoscopy was scheduled for two weeks before she left for college. 'I literally came out of my colonoscopy, and my doctor told me that I had [UC],' Cappelle said. She needed to overhaul her diet immediately. Individual triggers vary, but UC sufferers tend to experience flare-ups with high-fat foods, spicy foods and foods rich in insoluble fiber. Alcohol, caffeinated beverages and sugary drinks are often no-nos. Before her diagnosis, Cappelle typically had yogurt for breakfast, a sandwich with Cheez-Its for lunch and ground turkey, chicken or steak with potatoes or rice for dinner — or fast food. 'I definitely didn't eat well,' she admitted. 'If I wanted [Raising] Canes or Chick-fil-A, if I wanted fast food, I was going to go get the fast food.' She first axed spicy foods, including her beloved Flamin' Hot Cheetos and hot sauce, soda and gluten. Unfortunately, her stomach pain didn't go away right away. 'I was trying to eat whole foods, but obviously that's hard, especially being a freshman in college,' Cappelle said. 'You're living in a dorm, so you really don't have a kitchen.' She came home to the greater Houston area in December, cutting dairy and alcohol from her diet and stepping up her exercise routine. She also began working with a therapist and getting infusions of Entyvio, prescription medication that targets gut inflammation. Her stomach pain and bloody stool subsided, and she plans to return to Texas State in August. 'I think it'll be easier this next year, because I will have an apartment and my own kitchen,' Cappelle said. 'It is hard because you can't necessarily eat what everybody else is eating. But, for me, personally, it's not worth it to eat like that, knowing what could happen if I do eat like that.' She's been sharing her journey on TikTok, hoping to connect with people facing the same challenges. 'The hardest part for me [is] feeling so alone,' Cappelle said. 'I really just want to put the message out there of, you're not alone in this, and you can get better, and you will get better.'

Business Upturn
6 days ago
- Business Upturn
Live Biotherapeutics at a Crossroad: Novotech White Paper Outlines Opportunities and Early-Stage Challenges
Sydney, Australia: As Live Biotherapeutic Products (LBPs) begin to transition from frontier science to clinical reality, Novotech, a leading global CRO and scientific advisory partner has published a new white paper examining the opportunities and challenges shaping this fast-evolving landscape of therapeutic class. This press release features multimedia. View the full release here: LBPs, which harness live microorganisms to restore or modulate human health, are being explored across a growing range of indications, from gastrointestinal and metabolic disorders to CNS and oncology. FDA approvals of Rebyota™ and Vowst™ have validated the category but for most biotech sponsors, the journey remains uncertain. According to Novotech's analysis, over 90% of LBP assets are still in early development stages, and nearly one-third of all trials from 2020 to 2025 have been withdrawn or suspended due to regulatory, manufacturing, or design complexities. Highlights from the report include: A growing pipeline of preclinical and Phase I–II LBP candidates, with notable concentration in Alzheimer's, IBD, diabetes, and NASH. Over 90 industry-sponsored trials launched since 2020, yet 32% have experienced discontinuation. North America and Europe leading in regulatory approvals and manufacturing activity, with rising interest from biotechs in Asia-Pacific. A projected CAGR of 38% for the LBP and microbiome CDMO market through 2030. The global market for LBPs and microbiome contract development and manufacturing organizations (CDMOs) was valued at USD 31.84 million in 2023. With growing investment in players like Vedanta Biosciences and MaaT Pharma, the LBP field is maturing but also becoming more competitive. Success will depend on smart trial design, global regulatory navigation, and efficient feasibility execution. Drawing on deep therapeutic expertise in microbiome-related studies and gastrointestinal, metabolic, and immunologic indications, Novotech supports sponsors from early development through global trial delivery. With operations spanning Asia-Pacific, North America, and Europe, Novotech is uniquely positioned to help biotech and small to mid-size pharma companies translate LBP potential into clinical success. Download the full white paper 'Why Live Biotherapeutics Matter to Emerging Biotech' here. For further information, please visit About Novotech Novotech is a globally recognized full-service clinical research organization (CRO) and scientific advisory company trusted by biotech and small- to mid-sized pharmaceutical companies to guide drug development at every phase. With a global footprint that includes 30+ offices across the Asia-Pacific region, North America, and Europe and partnerships with 5,000+ trial sites, Novotech provides clients an accelerated path to bring life-changing therapies to market by providing access to key clinical trial destinations and diverse patient populations. Through its client-centric service model, Novotech seamlessly integrates people, processes, and technologies to deliver customized solutions that accelerate the path to market for life-changing therapies. By adopting a true partnership approach, Novotech shares a steadfast commitment to client success, empowering innovation, and advancing healthcare worldwide. Recipient of numerous industry accolades, including the Frost & Sullivan CRO Company of the Year award for 19 consecutive years, Novotech is recognized for its excellence in clinical trial execution and innovation. Its deep therapeutic and regulatory expertise, combined with local market insights, ensures streamlined clinical trials, optimized data analytics, and accelerated patient recruitment strategies. Together with clients, Novotech transforms scientific advancements into therapies that improve global health outcomes, embodying a mission of driving innovation and delivering impactful results. For more information or to speak to an expert team member visit View source version on Disclaimer: The above press release comes to you under an arrangement with Business Wire. Business Upturn takes no editorial responsibility for the same. Ahmedabad Plane Crash